Between November 5 and 7, in Frankfurt, Antibiotice Iasi is attending CPhI Worldwide 2019 (Convention on Pharmaceutical Ingredients), the most important global event of the pharmaceutical industry that brings together over 2,500 exhibitors from all over the world, this year expecting over 45,000 visitors. This major event represents a great opportunity to consolidate the business, to find out the latest news and trends of the pharmaceutical industry, and meet the most important players in this industry.
The Antibiotice team has planned firm meetings with over 170 business partners, together with the actions that will be discussed to capitalize on the company’s research and production infrastructure capabilities, in order to develop and secure the medium and long term business.
“In the 2020s there are no borders, and companies are present all over the world with their products. To support our development plan for the next 10 years, we must always be in touch with business partners, which is why we need to be present in such environments where we consolidate long-term business with our traditional employees and make ourselves known potential partners. We are concerned to develop our businesses mutually, to meet the needs of our partners, but also to validate their support in developing our future plans,” said Ioan Nani, the general director of Antibiotice.
This year marks the company’s seventeenth consecutive participation in this international fair, together with the elite of the global pharmaceutical market, aiming to strengthen the position of Antibiotice in its strategic territories, to identify new markets for both the active substance Nistatin, for which the company is a world leader, and for the 70 finished products registered on foreign markets, a reconfirmation of commercial relations with suppliers of raw materials and the identification of new sources of supply.
Antibiotice aims to become an internationally established manufacturer for topical (dermatological) products and at the same time is constantly concerned about remaining the leader on the sterile products (sterile injectable solutions and powders) segment and on the active substance Nistatin. In this regard, the business concepts promoted within the CPHI Worldwide 2019 fair target the portfolio of Hospital & Partners, the portfolio of dermatological, cardiological products, products for Quality of Life and Women’s Health as well as Nistatin.
Currently, Antibiotice is oriented towards identifying and originalizing those international territories comparable to the Romanian market, which use the same mechanisms, have the same types of products, the same programs for hospital and retail, to find a common expression in these territories. Following this principle and constantly concerned about facilitating the access of as many patients as possible to the products in its portfolio, Antibiotice develops a network of operational sales offices, ATB territories, in the Republic of Moldova, Vietnam, Ukraine and Serbia (Office), generating a long-term sustainable growth of the company’s business.
Antibiotics in foreign markets:
• World leader in the production of Nistatin, USP International Reference Standard. The main export market is the USA;
• USD 35 million estimated sales from export by the end of 2019;
• 34 percent of the turnover value was made in 2018 on international markets;
• Business partners in over 70 countries on all continents;
• Operational sales offices in Vietnam, Ukraine, Republic of Moldova and Serbia (Office)
• Internationally recognized certifications and authorizations:
– authorization from the US drug regulatory body (FDA) for the active substance Nistatin and injectable products;
– Certificate of Compliance with the European Pharmacopoeia (CoS) for Nystatin;
– Good Manufacturing Practice (GMP) certificate for all manufacturing flows.